Semax (ACTH Fragment Peptide)

What a Fragment Keeps Decides What It Does

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Fragments of one hormone can have entirely different properties because a hormone's functions are not distributed evenly along its sequence. Which residues a fragment keeps determines which of the parent's activities it can retain.

Key facts

Parent
alpha-MSH, 13 residues
Receptor-binding core
His-Phe-Arg-Trp, positions 6-9
Kept by
MT-2, which engages melanocortin receptors
Discarded by
KPV and, in part, Semax
KPV activity
Anti-inflammatory, C-terminal
Consequence
Same parent, incompatible profiles

Why function is not spread evenly

A receptor recognises a specific surface, and that surface is formed by particular residues rather than by the molecule as a whole. Other regions may contribute stability, solubility or a separate activity entirely. Cutting a hormone into pieces therefore separates functions rather than diluting them uniformly.

The receptor-binding core

For the melanocortin receptors the recognised core is His-Phe-Arg-Trp, positions 6 to 9 of alpha-MSH. A fragment retaining it can engage those receptors; one that does not, cannot. That single fact explains most of the divergence between the three compounds derived from this hormone.

Research material referenced

Semax 10mg, third-party HPLC tested

Buy Semax · £24.99

How each fragment lands

MT-2 is built around that core, cyclised and stabilised, and engages melanocortin receptors, which is the point of it. KPV is positions 11 to 13 and contains none of the core, which is why it was isolated: to keep the anti-inflammatory activity while discarding pigmentation. Semax retains positions 4 to 7, so it holds part of the core region and replaces the rest with Pro-Gly-Pro.

Why Semax is the ambiguous case

It keeps His and Phe, two of the four core residues, and replaces Arg-Trp-Gly. A partial core is neither clearly retained nor clearly discarded, which may be part of why Semax has no identified receptor while MT-2's target is well defined. Its described mechanisms are downstream and indirect rather than receptor-level.

The general lesson for fragment compounds

This site carries several: modified GRF from GHRH, and KPV and Semax from the POMC family. The recurring question is the same each time: which part of the parent's function did the fragment inherit, and which did it leave behind? Assuming a fragment carries the parent's properties is the standard error, and it is checkable against the sequence.

Regulatory position

None of these fragments holds a marketing authorisation anywhere. All are supplied for laboratory research only, and no claim is made about pigmentation, inflammation, cognition or any condition in any person.

Frequently asked questions

Why do fragments of one hormone differ so much?

Because function is not spread evenly along a sequence. Which residues a fragment keeps determines which activities it can retain.

Why does Semax have no identified receptor?

It retains only part of the core (His and Phe) and replaces the rest, so it is neither clearly a receptor ligand nor clearly not one.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Semax (ACTH Fragment Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.